Introduction {#s1}
============

Proton pump inhibitors (PPIs) are one of the most prescribed groups of drugs globally [@pone.0050836-IMS1]. PPIs are effective for the treatment of all acid-related disorders. They are also indicated ICU patients with coagulopathy, patients on mechanical ventilation, and patients with history of peptic ulcer disease, (particularly those on NSAID or antiplatelet therapy) [@pone.0050836-Yachimski1].

The use of PPIs has increased dramatically [@pone.0050836-IMS1] despite concerns that PPIs are overprescribed both in primary care [@pone.0050836-Batuwitage1] and in hospitals, both in the in-patient setting [@pone.0050836-Cahir1]--[@pone.0050836-Scagliarini1] and on discharge [@pone.0050836-Ahrens1]. Moreover, concerns have been raised about the potential long-term effects of these drugs. PPIs have been associated with significant interaction with other drugs [@pone.0050836-US1], [@pone.0050836-Charlot1] and fractures [@pone.0050836-Eom1], interstitial nephritis [@pone.0050836-Sierra1], pneumonia [@pone.0050836-Johnstone1] and enteric infections [@pone.0050836-Dial1], [@pone.0050836-Leonard1], namely *Clostridium difficile* infection (CDI).

CDI has recently emerged as a major public health problem with current estimates suggesting a point prevalence of 13.1/1000 in-patient population [@pone.0050836-Jarvis1]. Studies have reported increases in both incidence and mortality of CDI [@pone.0050836-Archibald1]--[@pone.0050836-Redelings1]. The increase in incidence of CDI has been attributed to an aging population, increase in use of antibiotics and acid suppressive drugs. PPIs are postulated to increase the proliferation of spores and change the acidic milieu of the stomach that permits spores to survive intraluminally.

The role of gastric acid suppression therapy has gained much interest recently as a risk factor for CDI. Four recently published meta-analyses have suggested an association between gastric acid suppression therapy with proton pump inhibitors (PPI) and CDI [@pone.0050836-Leonard1], [@pone.0050836-Kwok1], [@pone.0050836-Deshpande1], [@pone.0050836-Bavishi1]. The United States Food and Drug Administration (FDA) recently warned the public about a possible association between CDI and PPI use [@pone.0050836-Elixhauser1]. Nevertheless, these reviews had important limitations such as missing a large number of published studies [@pone.0050836-Leonard1], [@pone.0050836-Elixhauser1], [@pone.0050836-Deshpande1], [@pone.0050836-Bavishi1], using only unadjusted data from observational studies [@pone.0050836-Leonard1], [@pone.0050836-Deshpande1], [@pone.0050836-Bavishi1], not exploring heterogeneity and the effect of publication bias and over-interpreting the findings. We, therefore, performed a systematic review and meta-analysis that addressed the role of PPIs in CDI. We used the MOOSE [@pone.0050836-Stroup1] and PRISMA guidelines [@pone.0050836-Liberati1] for reporting systematic reviews. We include new studies published after the previous meta-analyses and added unique approaches to adjust for publication bias as well as explore the potential effect of unknown confounders. We use the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) framework [@pone.0050836-Guyatt1] to interpret our findings.

Methods {#s2}
=======

Study Search Strategy {#s2a}
---------------------

The search strategy and subsequent literature searches were performed by a medical reference librarian (PJE) with 38 years of experience. The initial strategy was developed in Ovid MEDLINE (1990 through January 2012), using MeSH (Medical Subject Headings) controlled vocabulary, and then modified for Ovid EMBASE (1990 through January 2012). The search was intended to capture all acid suppression studies. Primary terms were: enterocolitis, pseudomembranous/AND the therapeutic agents of interest: explode omeprazole, explode proton pump inhibitors, anti-ulcer agents, and explode histamine H~2~ antagonists (Explode allows including all of the specific drugs, without having to use all of the various terms, synonyms, brands and generic names.) Articles were limited to randomized controlled trials, cohort studies, and/or case-control studies. The same process was used with Ovid EMBASE with alterations as necessary to accommodate EMBASE's more granular subject headings. ISI Web of Science and Elsevier Scopus use textwords: (difficile OR pseudomembranous OR pseudo-membranous) AND (omeprazole OR "proton pump" OR ranitidine OR h2 OR h-2 OR "acid suppression" OR antacid\*)) AND (random\* OR trial\* OR blind\* OR cohort\* OR controlled OR prospective).

There was no restriction on language. All results were downloaded into EndNote 7.0 (Thompson ISI Research soft, Philadelphia, Pennsylvania), a bibliographic database manager, and duplicate citations were identified and removed. Two authors (A.B.A. and F.A.) independently assessed the eligibility of identified studies.

Study Selection {#s2b}
---------------

To be included, a study had to: (1) be an analytical study; and (2) have examined the association between PPI use and incidence of CDI.

Data Collection {#s2c}
---------------

A data collection form was developed and used to retrieve information on relevant features and results of pertinent studies. Two reviewers (A.B.A. and F.A.) independently extracted and recorded data on a predefined checklist. Disagreements among reviewers were discussed with two other reviewers (I.M.T. and M.A.), and agreement was reached by consensus. Data included the following: study characteristics (i.e., country and year of study), characteristics of the study, PPI intake definition and ascertainment, and outcome. We also collected adjusted effect estimates and 95% confidence intervals (CI) based on the multivariable regression model used in each study, and the list of variables considered for inclusion in the multivariate analysis.

We used the Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies [@pone.0050836-Wells1] which is intended to rate selection bias, comparability of the exposed and unexposed groups of each cohort, outcome assessment, and attrition bias. Two reviewers (A.B.A. and F.A.) independently assessed the methodological quality of selected studies using the Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies. Disagreement among reviewers was discussed with 2 other reviewers (I.M.T. and M.A.), and agreement was reached by consensus.

We used the GRADE framework to interpret our findings. The Cochrane Collaboration has adopted the principles of the GRADE system [@pone.0050836-Higgins1] for evaluating the quality of evidence for outcomes reported in systematic reviews.

For purposes of systematic reviews, the GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. Quality of a body of evidence involves consideration of within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias.

Statistical Analyses {#s2d}
--------------------

### Meta-analyses {#s2d1}

The primary effect measures used in the meta-analysis were Odds Ratios (OR) (46 observations), and Hazard Ratios (HR) (5 observations) which were assumed to reasonably estimate the same association between CDI and PPIs because of low CDI incidence and are pooled together. Adjusted effect estimates were primarily used for this analysis. Unadjusted effect estimates were used as alternatives if studies did not observe an association on univariate comparison and did not therefore pursue adjustment or did not report adjusted estimates. We performed meta-analyses for all studies together and separately for different subgroups such as case-control studies and cohort studies.

Effect estimates from all included studies were pooled in a meta-analysis using the DerSimonian and Laird random effects model [@pone.0050836-DerSimonian1].

### Exploring heterogeneity {#s2d2}

Homogeneity among studies was estimated by calculation of the variation across studies attributable to heterogeneity rather than chance (I^2^). The influence of a range of a-priori selected study-level and aggregated individual-level parameters on the observed effect estimate was investigated by means of meta-regressions. In these analyses, the log odds ratio from each study was regressed on the potential confounders in univariate and multivariate weighted linear regressions, weighted according to the inverse standard error and the residual between-study variance. Nine potential confounders were considered. Six variables were categorical: design of the study (case-control vs. cohort), country of publication, setting (single center vs. multicenter), method of ascertainment of antibiotic use, method of effect measure (OR vs. RR/HR) and effect estimate (adjusted vs. unadjusted). Three continuous variables were: the impact factor of the journal where the study was published, number of variables the effect measure was adjusted for and proportion of cases that were exposed to antibiotics.

### Publication bias {#s2d3}

The possible influence of publication bias was graphically assessed with the novel method of contour-enhanced funnel plot [@pone.0050836-Peters1] where log-transformed odds ratios were plotted against standard errors. This method examines whether any funnel plot asymmetry is likely to be due to publication bias compared with other underlying causes of funnel plot asymmetry. The contours help to indicate whether areas of the plot, where studies are perceived to be missing, are where studies would have statistically significant effect sizes or not and thus decrease or increase the evidence that the asymmetry is due to publication bias. The presence of funnel plot asymmetry was also assessed using Egger's test [@pone.0050836-Egger1]. To adjust for the impact of publication bias on the pooled effect estimate, we used a novel regression based adjustment method recently suggested by Moreno et al [@pone.0050836-Moreno1]. An adjusted pooled effect estimate for an ideal study of a very large size (i.e. with zero standard error) is obtained from the fitted weighted linear regression equation, plotted with a regression line on the contour enhanced funnel plot. This method of regression is a modified version of conventional Egger's regression test for publication bias where the log of effect estimate is regressed by its variance rather than the standard error and weights are assigned according to the inverse of the variance. This model has been shown to consistently outperform the conventional trim and fill method [@pone.0050836-Moreno1].

### Residual confounding {#s2d4}

Finally, the possible influence of unknown confounders (residual confounding) was investigated with a rule-out approach described by Schneeweiss [@pone.0050836-Schneeweiss1]. This approach stipulates the influence of a hypothetical confounder and determines what characteristics this confounder must have to fully account for the observed association between use of PPIs and occurrence of CDI. The hypothetical confounder is characterized by its association to PPIs use (OR~EC~, odds ratio of exposure to the confounder) and its association to the outcome (RR~CO~, relative risk of outcome in individuals exposed to the confounder vs. non-exposed). For this analysis, the absolute risk in the pooled non-exposed group was used for conversion of odds ratio to relative risk using the method described by Zhang and Yu [@pone.0050836-Zhang1]. Separate analyses were performed to demonstrate what levels of OR~EC~ and RR~CO~ would be required to fully explain the observed association between PPIs and CDI for different hypothetical prevalence of the unknown confounder (i.e. P~C~ = 0.2, P~C~ = 0.5) before and after adjustment for publication bias as described above.

In all analyses, results associated with p-values \<0.05 (two-sided test) were considered statistically significant. All statistical analyses were performed using Stata version12 statistical software (Stata Corp, College Station, Texas).

Results {#s3}
=======

Yield of Search Strategy and Eligible Studies {#s3a}
---------------------------------------------

The search strategy yielded 287 publications of which 242 were not eligible for inclusion based on title/abstract review. Reference lists of all eligible articles were systematically searched and 7 additional studies were identified that were not captured by our search strategy. A total of 47 citations, 4 of which reported data on 4 different populations, that examined the association between PPI therapy and CDI were eligible for this review. [Figure 1](#pone-0050836-g001){ref-type="fig"} summarizes the study selection process and is presented in the appendix.

![Flow diagram of eligible studies.](pone.0050836.g001){#pone-0050836-g001}

Characteristics of the Included Studies {#s3b}
---------------------------------------

[Table 1](#pone-0050836-t001){ref-type="table"} summarizes characteristics of the included studies. Studies were conducted in Asia, Europe, North America (Canada and USA). One citation reported both a case-control and cohort designs on 2 different patient populations [@pone.0050836-Dial2]. Three citations [@pone.0050836-Kutty1]--[@pone.0050836-Linney1] reported two different case control analyses per each citation. Forty analyses were single-centre, nine were multi-centre, and two from a general practice research database (GPRD). Thirty seven analyses were of case-control design and 14 were of cohort design. Among these, 8 exclusively addressed community-acquired CDI, 37 hospital-acquired and 6 both hospital- and community-acquired CDI. [Table S1](#pone.0050836.s001){ref-type="supplementary-material"} and [S2](#pone.0050836.s002){ref-type="supplementary-material"} summarizes the CDI case ascertainment and control or non-exposed group selection method for all studies.

10.1371/journal.pone.0050467.t001

###### Characteristics of the Included Studies.

![](pone.0050836.t001){#pone-0050836-t001-1}

  Source                         Country     Centers           Setting                  Condition             Study Design                                             Inclusion Criteria                                                                   Acid Suppression Therapy
  ----------------------------- --------- ------------- ---------------------- --------------------------- ------------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  Kutty et al (VA),^1^ 2010        US      Multicenter        Community                  Gen Pop              Case-control                                     Age: ≥18 yr; Community onset CDAD                                                         PPI exposure 3mo prior to test
  Kutty et al (D),^1^ 2010         US      Multicenter        Community                  Gen Pop              Case-control                            Age: ≥18 yr; Durham residence; Community onset CDAD                                                PPI exposure 3mo prior to test
  Southern et al,^2^ 2010          US      Multicenter         Hospital              Abd-surgery pts          Case-Control                              Positive CD within 30 d after surgery; diarrhea                                             PPI: exposure within 10d before surgery
  Nath et al,^3^ 1994              CA        Single            Hospital             Hem-oncology pts          Case-control                                          Adult; In-patient \> 3d                                                                 Acid suppressive therapy
  Jayatilaka et al,^4^ 2007        US        Single            Hospital              Gen In-patient           Case-control                                                  Age \>18                                                                      PPI pre or during admission
  Jayatilaka et al,^4^ 2007        US        Single            Hospital              Gen In-patient           Case-control                                                  Age \>18                                                                          PPI: post admission
  Branch et al,^5^ 2007            US        Single            Hospital              Gen In-patient           Case-control                                           Age ≥18yr ; In-patient                                        PPI: 3d before testing or 7d within the last month; before hospitalization
  Al-Tureihi et al,^6^ 2005        US        Single            Hospital                 LTCF pts              Case-control                           Positive CD toxin; documented diagnosis/ ABX for CDAD                                                            PPI
  Shah et al (D),^8^ 2000          UK        Single            Hospital              Gen In-patient           Case-control                               Age \> 65 yr; Gen medical/ elderly care wards                                                  PPI: up to 16wk before diarrhea
  Dial et al,^11^ 2005             UK         GPRD            Community                  Gen Pop              Case-control      Age ≥18 yr ; At least 2 yrs of records in the GPRD prior to index date; first occurrence of CDAD                        PPI: 90d prior to the index date
  Akhtar et al,^12^ 2007           US        Single            Hospital              Gen In-patient           Case-control                       Afro-American/ Hispanic pts admitted with diarrhea positive CD                                             PPI: 3m before diarrhea
  Dial et al,^13^ 2006             UK         GPRD            Community                  Gen Pop              Case-control        All pts with first prescription oral Vancomycin; No previous admission 1yr before index date                          PPI: 90d prior to the index date
  Asseri et al,^14^ 2008           US        Single            Hospital              Gen In-patient           Case-control                                         Age ≥18 Yr; Inpt for ≥3 d                                                              PPI: at least 3d before CDAD
  Cunningham et al,^15^ 2003       UK        Single            Hospital              Gen In-patient           Case-control                                                     NR                                                                              PPI: preceding 2mo
  Dubberke et al,^16^ 2007         US        Single            Hospital              Gen In-patient           Case Control                        Pts admitted for \> 48 hr between study period were included                                                        PPI
  Dial et al,^17^ 2004             CA        Single            Hospital              Gen In-patient         Case-control, (P)        In- pts with CDAD; Positive toxin result during or within m after the index admission             PPI : at least 3d before diarrhea ; 3d in hospital if no diarrhea
  Loo et al,^18^ 2005              UK        Single            Hospital              Gen In-patient           Case-control                                          Hospital Acquired CDAD;                                                                PPI: 6wk before diagnosis
  Sundram et al,^19^ 2009          UK        Single            Hospital              Gen In-patient           Case-control                                        Adult Hospital Acquired CDAD                                                          PPI: 6wk prior to onset of CDAD
  Howell et al,^29^ 2007           US        Single            Hospital              Gen In-patient              Cohort                                   Age ≥ 18 yr; LOS ≥3 d; Only first diagnosis                                                              Daily PPI
  Dalton et al,^30^ 2009           CA      Multicenter         Hospital         Med/Surgical Subspecialty     Cohort , (R)                                 Age: ≥18 yr; Minimum 7-d LOS; ABX exposure                                                         PPI Days: 18.7±21.5
  Dubberk et al,^31^ 2007          US        Single            Hospital              Gen In-patient            Cohort, (R)                               All pts admitted to BJH for more than 48 hours                                                               PPI
  Pépin et al,^32^ 2005            CA        Single            Hospital              Gen In-patient            Cohort, (R)                                              Adult In-patient                                                                              PPI
  Beaulieu et al,^33^ 2007         CA        Single            Hospital                Medical ICU               Cohort           LOS in ICU\>24hr ; Diarrhea \>24 hr and positive CD toxin between 2d to 2mo after discharge                                         PPI
  Peled et al,^34^ 2007            IL        Single            Hospital              Gen In-patient           Cohort , (P)                       CD testing during 4m period; ABX within 40d prior to diarrhea                                                        PPI
  Dial et al,^17^ 2004             CA        Single            Hospital           Med/CT surgical wards          Cohort           Pharmacy database; ABX during study period; positive toxin in the infection control registry                                        PPI
  Linsky et al,^28^ 2010           US      Multicenter   Community & Hospital            Gen Pop              Cohort , (R)         First positive CD toxin, VA health care system use for 1 yr before or after the index CDAD                         PPI: Concurrent with CDAD Treatment
  Baxter et al,^7^ 2008            US        Single            Hospital              Gen In-patient           Case control                                                 In-patient                                                                      PPI: 60d before index date
  Debast et al,^20^ 2009           NL        Single           Hospital\*             Gen In-patient           Case control                                              Age:≥18 yr; CDAD                                                                      PPI: In the past 3mo
  Yearsley et al,^10^ 2006         UK        Single            Hospital              Gen In-patient         Case control, (P)                                             Age \> 18 yr                                                                    PPI: 3m prior to study entry
  Lowe et al,^9^ 2006              CA        Single           Community                  Gen Pop            Case control, (R)         1 hospital admission for CDAD; Age ≥ 66yr; CDAD diagnosis within 60d of ABX therapy                           PPI : upto 365d prior to the index date
  Novell et al,^21^ 2010                     Single            Hospital              Gen In-patient         Case control, (R)                                           Age:≥18 yr; CDAD                                                                              PPI
  Hensgens et al,^22^ 2011         NL        Single            Hospital              Gen In-patient         Case control, (P)                                 All hospitalized patients with CDAD                                                                     PPI
  Netland et al,^35^ 2011          US        Single      Community & Hospital            Gen Pop              Cohort , (R)                                               Recurrent CDAD                                                                               PPI
  Ingle et al,^36^ 2011          Ind-ia      Single      Community & Hospital            Gen Pop              Cohort , (R)                                           All patients with CDAD                                                                           PPI
  ♦Monge et al,^27^ 2011         Sp-ain      Single            Hospital                    NA                 Case control                                                     NA                                                                                     PPI
  Jenkins et al,^23^ 2010          UK        Single            Hospital                                     Case control, (R)                                   Post Hip/Knee replacement, CDAD                                                                       PPI
  Shaughnessy et al,^37^ 2011      US        Single            Hospital                Medical ICU             Cohort, (R)                                      All patients with CDAD diagnosis                                                                      PPI
  Kim et al,^38^ 2010              CA        Single            Hospital              Gen In-patient           Cohort , (R)                                         Age:≥18 yr; Recurrent CDAD                                                                         PPI
  Loo et al,^39^ 2011              CA      Multicenter         Hospital              Gen In-patient              Cohort                                      Age:≥18 yr; healthcare associated CDAD                                                                   PPI
  Manges et al,^24^ 2010           CA        Single            Hospital              Gen In-patient           Case control                                              Nosocomial CDAD                                                                               PPI
  Kuntz et al,^26^ 2011            US        Single           Community                  Gen Pop            Case control, (R)                                       Community acquired CDAD                                                                 Acid suppressive therapy
  Naggie et al,^25^ 2011           US      Multicenter        Community                  Gen Pop            Case control, (R)                                              Age:≥18 yr                                                                       Acid suppressive therapy
  Stevens et al,^40^ 2011          US        Single            Hospital              Gen In-patient              Cohort                   Age:≥18 yr; hospital acquired; non-psychiatric ward; exposed to antibiotics                                                 PPI
  Dial et al,^46^ 2008             CA      Multicenter        Community             Elderly patients          Case control                                     Age ≥65, Community Associated CDAD                                                                     PPI
  McFarland et al,^42^ 2007        US      Multicenter           Both                    Gen Pop              Case control                                               CDAD Diagnosis                                                                               PPI
  Kazakova et al,^47^ 2012         US        Single              Both                    Gen Pop              Case control             CDAD Diagnosis, onset during the pre-outbreak or outbreak periods, hospitalization                                             PPI
  Modena et al,^43^ 2005           US        Single              Both                    Gen Pop              Case control                     Received at least 5 days of antibiotics prior to diagnosis of CDAD                                                     PPI
  Muto et al,^44^ 2005             US        Single            Hospital              Gen Inpatients           Case control                                              Nosocomial CDAD                                                         PPI: During the 4 weeks before detection of CDAD
  Yip et al,^45^ 2001              CA        Single            Hospital              Gen Inpatients           Case control                                              Nosocomial CDAD                                                                               PPI
  Linney et al,^41^                CA        Single            Hospital              Gen Inpatients           Case control                                     Nosocomial, onset during outbreak.                                                PPI being taken on the date of CDAD diagnosis
  Linney et al,^41^                CA        Single            Hospital              Gen Inpatients           Case control                                     Nosocomial, onset during outbreak.                                              PPI being taken before the date of CDAD diagnosis

♦ NA: Data obtained from abstract

Legend: OR: odds ratio; HR: harzard ratio; CDAD: *Clostridium difficile-*associated diarrhea; PPI: Proton pump inhibitor; H2RA: VA: Veteran Affairs; D: Durham County, P: Prospective; R: Retrospective, ABX: Antibiotic; GPRD: General Practice Research Database; ICU: Intensive care unit

Metabolic processes are controlled by a variety of enzymes. For instance, cytochrome P450 monooxygenase could detoxify herbicides such as fenoxaprop-ethyl, diclofop-methyl, and bentazon in plants [@pone.0050836-Deshpande1], [@pone.0050836-Bavishi1]. Polyphenol oxidase (PPO), commonly found in fungi and plants, refers to a group of enzymes that catalyze the oxidation of phenolic compounds [@pone.0050836-Stroup1]. Peroxidase (POD), another type of oxidative enzyme commonly present in plant and animal tissues, can oxidize phenols and aromatic amines in the presence of hydrogen peroxide. In contrast, the oxidation of phenolic compounds by PPO requires the presence of oxygen gas [@pone.0050836-Liberati1]. Both PPO and POD play important roles in the metabolism of aromatic compounds in soil and water [@pone.0050836-Guyatt1], [@pone.0050836-Wells1]. However, little information is available regarding their function in the metabolism of PAHs by plants.

Quality Assessment of Included Studies {#s3c}
--------------------------------------

Quality assessment of all included studies was done using the validated Newcastle-Ottawa Quality Assessment Scale [@pone.0050836-Wells1] for cohort and case control studies ([Table S3](#pone.0050836.s003){ref-type="supplementary-material"} and [Table S4](#pone.0050836.s004){ref-type="supplementary-material"}). Most studies were of good quality with no evidence of selection bias, and with good comparability of the exposed and unexposed groups of each cohort, and outcome assessment. Fifty-one individual effect estimates from 47 eligible citations were extracted. We identified 2 outliers and excluded them from the final analyses as per the Cochrane Handbook for Systematic Reviews [@pone.0050836-http1]. The 2 outliers were: Bajaj et al [@pone.0050836-Bajaj1] because of a high OR = 37.6, and Wilcox et al [@pone.0050836-Wilcox1] because of large SE (SE log OR = 3.59). Final interpretation was based on analyses of the 51 observations.

Meta-analysis {#s3d}
-------------

### Association between PPI and CDI {#s3d1}

Fifty one individual effect estimates from 47 eligible studies were extracted. [Figure 2](#pone-0050836-g002){ref-type="fig"} shows the results of the pooled estimates for the 51 observations. The pooled OR for the 51 observations was 1.65, 95% CI (1.47, 1.85), I^2^ = 89.9%. [Table 2](#pone-0050836-t002){ref-type="table"} summarizes the pooled estimates and associated heterogeneity for different subgroups. All estimates supported an association between PPI therapy and CDI.

![Forest Plot of the Meta analyses of The Association Between CDI and Proton Pump Inhibitors Based on 51 Observations.](pone.0050836.g002){#pone-0050836-g002}

10.1371/journal.pone.0050836.t002

###### Influence of study type, country, weather effect estimate adjusted or not and PPI ascertainment method on the pooled effect estimate and its associated heterogeneity.

![](pone.0050836.t002){#pone-0050836-t002-2}

  Group                                             Pooled Effect Estimate 95% CI   I^2%^   Number of Observations
  ------------------------------------------------ ------------------------------- ------- ------------------------
  All citations                                           1.65 (1.47, 1.85)         89.9              51
  Case-control citations                                  1.70 (1.42, 2.03)         88.7              37
  Cohort citations                                        1.64 (1.30, 2.08)         87.8              14
  Asia                                                    3.26(1.91, 5.58)           0.0              3
  Canada                                                  1.22 (1.09, 1.37)         82.1              14
  Europe                                                  1.90 (1.35, 2.66)         75.5              10
  USA                                                     1.70 (1.41, 2.04)         73.3              24
  Studies reported adjusted effect estimates\*            1.78 (1.56, 2.02)         92.2              37
  Studies reported unadjusted effect estimates\*          1.27 (0.93, 1.71)         59.4              14
  PPI ascertainment method (Chart)^†^                     1.89 (1.45, 2.45)         93.6              20
  PPI ascertainment method (Interview)^†^                 1.17 (0.91, 1.51)         79.0              8

### Exploring heterogeneity {#s3d2}

The influence of a range of a-priori selected study-level and aggregated individual-level parameters on the observed effect estimate was investigated by means of meta-regressions. [Table S5](#pone.0050836.s005){ref-type="supplementary-material"} summarizes the meta-regression analyses for all 51 results and is presented in the appendix. We observed that studies that used interviews to ascertain PPI exposure had on average lower effect estimates that studies that used medical records 1.17 (0.91, 1.51) vs. 1.89 (1.45, 2.45), p for interaction = 0.05 ([Table 2](#pone-0050836-t002){ref-type="table"}). We also observed that studies that used adjusted effect estimates \[1.76 (95% CI, 1.54, 2.00)\] had higher pooled estimates than those that used unadjusted effect estimates \[1.27 (95% CI, 0.93, 1.72)\], p = 0.07.

### Publication bias {#s3d3}

[Figure 3](#pone-0050836-g003){ref-type="fig"} displays a contour-enhanced funnel plot with the corresponding fixed (FE) and random effect (RE) meta-analyses pooled estimates providing a weighted average of effect size across studies of 1.02 (95% CI, 1.01--1.03) and 1.65 (95% CI, 1.47--1.85) respectively. There was visual evidence of funnel asymmetry and Egger's test for publication bias, P = 0.001. Hence, a novel regression based method was used to adjust for publication bias.

![Contour enhanced funnel plot of the association between the effect-estimates and its standard errors:\
\* Contour enhanced funnel plots with implementation of regression adjustment model (adjusted effect at top where SE is 0).\* The contour lines differentiate the significance and non-significance regions in the plot at 1%, 5% and 10% significance levels. \*Vertical lines show average effect-estimates from random effect (red), and fixed effect models (blue). \*A regression line (black) is added for regression based adjustment (With adjusted effect estimate and 95% CI at top where SE is 0). Abbreviations: FEMA: Fixed effect meta-analysis, REMA: Random effect meta-analysis, Reg: Regression line.](pone.0050836.g003){#pone-0050836-g003}

The fitted regression line plotted in [Figure 3](#pone-0050836-g003){ref-type="fig"} corresponds to the regression-based adjustment method. The adjusted estimate is obtained by extrapolating the line with a standard error of 0 (at the top of the funnel plot). This produced an adjusted average effect estimate (RE model) of 1.51 (95% CI, 1.26--1.83).

### Residual confounding {#s3d4}

The results of the residual confounding analysis are presented in [Figure 4](#pone-0050836-g004){ref-type="fig"}. Panel A refers to a confounder with a prevalence of 0.20 and at this prevalence level, even a strong confounder causing a 2.5-fold increased risk of CDI would have to be imbalanced between acid-suppression users and non-users (OREC = 3.8) to fully account for the observed adjusted RR of 1.32 (adjusted for publication bias). For a very common confounder with a prevalence of 0.50 (Panel B) and causing a 2.5-fold increased risk of CDI, it would have to be distinctly imbalanced between acid-suppression users and non-users (OREC = 5.38) to fully account for the observed adjusted RR of 1.32.

![Influence of a hypothetical dichotomous confounder present in 20% (panel A) and 50% (panel B) of the study population, unaccounted for in the adjustments already performed in the individual studies.\
The graphs indicate what combinations of OREC and RR that would be necessary for the confounder to fully account for the observed association between proton pump inhibitor (PPI) use and CDAD after adjustment for publication bias. Abbreviations: OR~EC~, odds ratio of exposure to the confounder in PPI non-users vs. acid-suppression users; RR~CD~, relative risk of CDAD in individuals exposed to the confounder vs. non-exposed.](pone.0050836.g004){#pone-0050836-g004}

Number Needed to Harm {#s3e}
---------------------

The number needed to harm (NNH) was estimated by using the pooled OR from the meta-analysis [@pone.0050836-Lowe1]. This analysis is only speculative as it assumes there is a cause-effect relationship between PPI and CDI. A recent large prospective hospital cohort [@pone.0050836-Howell1] reported the incidence of CDI at 14 days after hospital admission in patients receiving antibiotics or not: which was 42/1,000 and 5.4/1000, respectively. Based on these reported baseline risks, the number needed to harm (NNH) was 50, 95% CI (31, 97) and 367, 95% CI (226, 718), respectively. For the general population, the NNH at 1 year was 3925, 95% CI (2412, 7698) at 1 year, based on a baseline incidence of CDI of 48/100,000 person-years [@pone.0050836-http1].

Discussion {#s4}
==========

Findings {#s4a}
--------

In this rigorously conducted systemic review and meta-analysis, we observed a weak association between PPI use and risk of CDI. This association was further weakened by the presence of significant heterogeneity. Although we adjusted for publication bias and ruled out a strong effect of an unmeasured confounder, the cumulative evidence provided by this systematic review constitutes only very low quality evidence (as per GRADE framework) in favor of this association. Factors that negatively influence the quality of the evidence include the observational design, inconsistency of results, and evidence of publication bias.

Moreover, *even if we assume that the pooled effect estimate is valid*, the absolute risk of CDI would be very low in the general population with an estimated NNH of 3925 at 1 year. In contrast, the risk would behighest in hospitalized patients receiving antibiotics with an estimated NNH of 50 at 2 weeks.

Comparison to Other Studies {#s4b}
---------------------------

Several systematic reviews [@pone.0050836-Leonard1], [@pone.0050836-Kwok1]--[@pone.0050836-Bavishi1], [@pone.0050836-Available1], [@pone.0050836-Janarthanan1] examining this association have been published previously; however, our review is the most comprehensive and is unique in its analytical approach and interpretation and thus adds substantially to the cumulative evidence. [Table 3](#pone-0050836-t003){ref-type="table"} summarizes the differences between our systematic and those recently published. First, our review identified the largest number of studies published to date. For example, our review has 36% more studies than the largest meta-analysis by Kowk et al [@pone.0050836-Kwok1] and 90% more studies that the recent FDA review published in February 2012. Second, our meta-analysis included adjusted effect estimates of the association between PPI and CDI. Third, we used meta-regression to explore sources of heterogeneity. None of the published analyses used this method. Fourth, we examined the effect of publication bias using a novel approach of contour-enhanced funnel plot [@pone.0050836-Moreno2]. The largest and most recent analysis by Kowk et al. [@pone.0050836-Kwok1] did not examine the effect of publication bias. Fifth, we used a novel regression-based method to adjust the pooled estimate for publication bias and we examined the potential effect of a residual confounding on the observed association using the rule-out approach.

10.1371/journal.pone.0050836.t003

###### Summary of reviews of the association between PPI use and *Clostridium Difficile* infection.

![](pone.0050836.t003){#pone-0050836-t003-3}

  Study                                                Search Engines                         Date     Acid suppression   Number of observations             Pooled effect estimates              Heterogeneity                                                Exploring heterogeneity                                                     Publication bias assessment         Residual confounding
  -------------------------------- ------------------------------------------------------- ---------- ------------------ ------------------------ ---------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ----------------------
  Tleyjeh et al (Present review)    Medline EMBASE ISI Web of Science and Elsevier Scopus   Jan 2012         PPI                    51                          1.65 (1.47, 1.85)                 I^2^ = 89.9%                                                     Meta-regression                                                    Contour-enhanced funnel plot asymmetry    Rule-out approach
  FDA Alert, ^44^                                       Not available                          NR            PPI                    28               Systematic review only No meta-analysis           NA                                                                NA                                                                             NA                              NA
  Kwok et al,^21^ 2012                                 Medline EMBASE                       Dec 2011         PPI                    39                          1.74 (1.47--2.85)                  I^2^ = 85%     Sensitivity analyses: -Case-control -Cohort -Lab. Confirmation -Inpatient -Community or mixed -Adjusted estimates                Not assessed                    Not assessed
  Bavishi and Dupont, ^23^ 2011                            Medline                          May 2011         PPI                    27               Systematic review only No meta-analysis           NA                                                                NA                                                                             NA                              NA
  Janarthanan et al,^45^ 2012                              Medline                          Dec 2010         PPI                    23                         1.69 (1.395--1.974)                I^2^ = 91.9%                                         Subgroup analysis: Case-control -Cohort                                           Funnel plot: possible asymmetry           Not assessed
  Deshpande et al,^22^ 2012           Medline CINAHL Cochrane Web of Science and Scopus     Oct 2010         PPI                    30             2.15 (1.81--2.55) **[Unadjusted data]{.ul}**    I^2^ = 87%                                         -Case-control -Cohort -% antibiotic used                                              Funnel plot: no asymmetry              Not assessed
  Leonard et al,^15^ 2007                          Medline CINAHL EMBASED                     2005           PPI                    11             2.05 (1.47--2.85) **[Unadjusted data]{.ul}**     P\<0.001                                                        Not assessed                                                            Funnel plot: no asymmetry              Not assessed

Legend: PPI: Proton pump inhibitor; NA: Not available.

Finally, we interpret the results in the context of observed limitations and therefore, draw more careful conclusions. Contrary to other reviews and FDA alert, we conclude that current cumulative data constitutes very low quality evidence. Our results are helpful for guidelines writing committees and policy makers that use the GRADE framework when formulating recommendations for use of PPI for different clinical indications.

Biologic Plausibility {#s4c}
---------------------

The mechanism by which PPI therapy contributes to an increased risk of CDI is unclear, because gastric acid does not kill gastric *C. difficile* spores. This further makes a cause-effect relationship a less likely explanation for the observed association.

It has been proposed that the vegetative form of *C. difficile*, which is killed by acid, plays a role in pathogenesis. Vegetative forms survive on surfaces and could be ingested by patients [@pone.0050836-Jump1]. Survival of these acid-sensitive vegetative forms in the stomach could be facilitated by 2 main factors: (1) suppression of gastric acid production by acid-suppressive medications; and (2) presence of bile salts in gastric contents of patients on acid-suppressive therapy. Bile salts, which are mainly found in the small intestine, are present in gastric contents, particularly among patients with gastro-esophageal reflux disease (GERD). Moreover, PPI use can delay gastric emptying and predispose to bacterial overgrowth with associated high intragastric bile salts which could trigger spore germination in the stomach [@pone.0050836-Wilson1]--[@pone.0050836-Thorens1].

However, a recent in vitro experiment has challenged these postulated biological mechanisms for the observed association. In this experiment, aspirate of gastric contents from hospitalized patients with nasogastric tubes were collected. It concluded that *C. difficile* spores were not killed in acidic gastric content and did not germinate in gastric contents of hospitalized patients on PPI. Germination occurred with the addition of taurocholic acid [@pone.0050836-Nerandzic1].

Limitations {#s4d}
-----------

There are limitations to our work. First, observational studies are subject to inherent limitations in the study design leading to unmeasured differences in the study population and unmeasured confounders despite all possible adjustments. PPIs use may be a surrogate of comorbidities and thus, the observed association may have been affected by selective overuse of PPIs in high risk groups. For example, the potential interaction between PPIs and Clopidogrel found in observational studies was refuted in randomized controlled trials [@pone.0050836-Bhatt1]. Second, the use of PPIs was based on electronic and prescription records, rather than by actual use by the patient. Third, there is presence of publication bias, and substantial amount of heterogeneity in the included studies. There are many patient level parameters which may have led to substantial heterogeneity. Nevertheless, investigating these variables is only possible with individual patient data meta-analysis. Fourth, all statistical methods used to assess for publication bias or residual confounding are subject to certain assumptions and have inherent limitations. For example, funnel plot asymmetry can be due to between studies heterogeneity rather than publication bias [@pone.0050836-Egger1].

Given these limitations, focus on hand hygiene as one of the cornerstones of prevention of nosocomial transmission of *C. difficile* is warranted. Several studies have documented the reduction of rates of hospital acquired infection by improvement in the compliance with hand washing by healthcare workers between episodes of contact with patients [@pone.0050836-Boyce1].

Conclusions {#s4e}
-----------

In this rigorously conducted systemic review and meta-analysis, we found very low quality evidence in support of an association between PPI use and risk of CDI. This association was weakened by the presence of significant heterogeneity and publication bias. Our findings are re-assuring that PPIs use in the general population does not pose a significant CDI risk. On the other hand, our findings warrant judicious and evidence-based use of PPI in patients at high risk for CDI.
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